Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
|
+$596M |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$429M |
| 3 |
Verizon
VZ
|
+$399M |
| 4 |
Amgen
AMGN
|
+$214M |
| 5 |
Citizens Financial Group
CFG
|
+$212M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MBS ETF
MBB
|
+$561M |
| 2 |
iShares National Muni Bond ETF
MUB
|
+$535M |
| 3 |
Oracle
ORCL
|
+$144M |
| 4 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$143M |
| 5 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.17% |
| 2 | Financials | 13.07% |
| 3 | Healthcare | 12.05% |
| 4 | Consumer Discretionary | 10.98% |
| 5 | Industrials | 9.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Blink Charging
BLNK
$74.3M
| $3.65M | ﹤0.01% |
88,591
+77,406
| +692% | +$2.87M |
|
|
EAR
2502
DELISTED
Eargo, Inc. Common Stock
EAR
| $3.63M | ﹤0.01% |
4,552
+1,300
| +40% | +$1.09M |
|
2503
Anavex Life Sciences
AVXL
$255M
| $3.63M | ﹤0.01% |
158,853
+10,214
| +7% | +$151K |
|
|
TRUE
2504
DELISTED
TrueCar
TRUE
| $3.63M | ﹤0.01% |
642,603
-26,246
| -4% | -$132K |
|
2505
Phathom Pharmaceuticals
PHAT
$708M
| $3.63M | ﹤0.01% |
107,120
+19,864
| +23% | +$711K |
|
2506
Talos Energy
TALO
$2.53B
| $3.62M | ﹤0.01% |
231,326
+52,438
| +29% | +$725K |
|
|
FSP
2507
Franklin Street Properties
FSP
$47.2M
| $3.6M | ﹤0.01% |
684,772
-76,993
| -10% | -$413K |
|
|
VAPO
2508
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $3.6M | ﹤0.01% |
19,005
+1,062
| +6% | +$181K |
|
2509
Mercado Libre
MELI
$95.2B
| $3.59M | ﹤0.01% |
2,307
-38
| -2% | -$55.8K |
|
|
NGM
2510
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $3.59M | ﹤0.01% |
182,110
+18,137
| +11% | +$425K |
|
|
SFT
2511
DELISTED
Shift Technologies, Inc. Class A Common Stock
SFT
| $3.58M | ﹤0.01% |
41,708
+14,634
| +54% | +$1.17M |
|
|
NPTN
2512
DELISTED
NEOPHOTONICS CORP
NPTN
| $3.58M | ﹤0.01% |
350,216
-50,079
| -13% | -$529K |
|
2513
Stratasys
SSYS
$679M
| $3.57M | ﹤0.01% |
137,931
+13,775
| +11% | +$314K |
|
|
FRTA
2514
DELISTED
Forterra, Inc
FRTA
| $3.56M | ﹤0.01% |
151,607
+2,674
| +2% | +$62.6K |
|
2515
Ocular Therapeutix
OCUL
$1.79B
| $3.54M | ﹤0.01% |
249,425
+7,128
| +3% | +$108K |
|
2516
Immunovant
IMVT
$7.93B
| $3.54M | ﹤0.01% |
334,436
+2,949
| +0.9% | +$41.2K |
|
|
RNAM
2517
DELISTED
Avidity Biosciences
RNAM
| $3.53M | ﹤0.01% |
142,959
-746
| -0.5% | -$17.4K |
|
2518
Invesco Short Term Treasury ETF
TBLL
$2.61B
| $3.53M | ﹤0.01% |
33,432
-6,443
| -16% | -$681K |
|
|
AUD
2519
DELISTED
Audacy, Inc.
AUD
| $3.53M | ﹤0.01% |
819,343
+15,010
| +2% | +$68.9K |
|
2520
Eos Energy Enterprises
EOSE
$1.22B
| $3.52M | ﹤0.01% |
196,126
+40,268
| +26% | +$649K |
|
2521
Forrester Research
FORR
$223M
| $3.52M | ﹤0.01% |
76,843
+1,341
| +2% | +$57.8K |
|
2522
Nuvation Bio
NUVB
$2.2B
| $3.52M | ﹤0.01% |
377,536
+82,092
| +28% | +$936K |
|
2523
Gevo
GEVO
$360M
| $3.5M | ﹤0.01% |
482,028
+413,790
| +606% | +$3.02M |
|
2524
VSE Corp
VSEC
$5.45B
| $3.5M | ﹤0.01% |
70,664
+2,345
| +3% | +$108K |
|
|
KRON
2525
DELISTED
Kronos Bio
KRON
| $3.5M | ﹤0.01% |
146,051
+50,690
| +53% | +$1.28M |
|
Similar funds
Charles Schwab's Q2 2021 Portfolio in Review
As of Q2 2021, Charles Schwab held 3,648 positions worth $301B, up 10% from $273B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q2 2021 filing shows 163 new, 2,481 increased, 676 reduced and 240 closed positions. Its largest new stake was Vanguard Intermediate-Term Treasury ETF: 6,338,757 shares worth $430M. The largest sale was iShares MBS ETF, an estimated $561M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q2 2021 buy was Vanguard Intermediate-Term Treasury ETF: 6,338,757 shares worth $430M.
- Charles Schwab added most to iShares 1-5 Year Investment Grade Corporate Bond ETF in Q2 2021, an estimated $596M increase.
- Charles Schwab's biggest Q2 2021 reduction was iShares MBS ETF, cutting an estimated $561M.
- Charles Schwab fully exited Invesco S&P 500 Low Volatility ETF in Q2 2021, selling an estimated $92.7M.
- Charles Schwab's ten largest holdings make up 17% of its $301B portfolio in Q2 2021.
- Charles Schwab opened 163 new positions and closed 240 in Q2 2021.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $301B.
Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.